Streetbeat News

Analyst Ratings

VRTX

Stifel analyst Paul Matteis maintains a 'Hold' rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $340 to $373.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:14 pm

THS

Stifel analyst Matthew Smith maintains a 'Hold' rating on Treehouse Foods (NYSE:THS) and lowers the price target from $47 to $42.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:13 pm

TGLS

Stifel analyst Stanley Elliott maintains a Buy rating on Tecnoglass (NYSE:TGLS) but has lowered the price target from $57 to $46.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:12 pm

SBRA

Stifel analyst Stephen Manaker maintains a 'Buy' rating on Sabra Health Care REIT (NASDAQ:SBRA) and raises the price target from $14 to $16.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:11 pm

O

Stifel analyst Simon Yarmak has maintained a 'Buy' rating on Realty Income (NYSE:O) but lowered the price target from $69.5 to $67.5.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:09 pm

NYXH

Stifel analyst Jonathan Block has maintained a 'Buy' rating on Nyxoah (NASDAQ:NYXH) but lowered the price target from $14 to $10.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:06 pm

IFF

Stifel analyst Mark Astrachan maintains a 'Hold' rating on Intl Flavors & Fragrances (IFF) and raises the price target from $77 to $87.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:05 pm

AZN

AstraZeneca has presented new evidence from its TULIP Phase III program showing that SAPHNELO (anifrolumab-fnia), a first-in-class biologic for patients with systemic lupus erythematosus (SLE), is more likely to achieve and sustain remission compared to standard therapy alone. The data will be presented at the annual meeting of the American College of Rheumatology (ACR). The company also highlighted positive results from the FASENRA (benralizumab) MANDARA Phase III trial, the first head-to-head trial of biologics to treat eosinophilic granulomatosis with polyangiitis (EGPA).

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:04 pm

INSP

Stifel analyst Jonathan Block has maintained a 'Buy' rating on Inspire Medical Systems (NYSE:INSP) but lowered the price target from $350 to $250.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:03 pm

EVCM

Stifel analyst Brad Reback has maintained a 'Buy' rating on EverCommerce (NASDAQ:EVCM) but lowered the price target from $14 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:02 pm